公开(公告)号：BRPI0712667A2

公开(公告)日：2012-09-04

申请号：BRPI0712667

申请日：2007-06-27

Applicant: ABBOTT LAB

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  LYNCH CHRISTOPHER L ,  GOPALAKRISHNAN MURALI ,  GOPALAKRISHNAN SUJATHA ,  MALYSZ JOHN ,  GUBBINS EARL J ,  EL KOUHEN RACHID ,  LI JINHE

IPC: C07D207/34 ,  A61K31/402 ,  A61P25/00 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10

Abstract: The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：CA2440238C

公开(公告)日：2011-09-13

申请号：CA2440238

申请日：2002-03-11

Applicant: ABBOTT LAB

Inventor： COWART MARLON D ,  BENNANI YOUSSEF L ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  BLACK LAWRENCE A

IPC: C07D307/79 ,  A61K31/343 ,  A61K31/4025 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/55 ,  A61P1/00 ,  A61P1/08 ,  A61P3/04 ,  A61P7/08 ,  A61P9/00 ,  A61P9/10 ,  A61P11/02 ,  A61P11/06 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61P43/00 ,  C07D307/81 ,  C07D311/18 ,  C07D333/54 ,  C07D405/04 ,  C07D405/06 ,  C07D405/14 ,  C07D407/04 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D491/10 ,  C07D521/00

Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.

公开(公告)号：MX2011003435A

公开(公告)日：2011-05-02

申请号：MX2011003435

申请日：2009-09-28

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  NERSESIAN DIANA L ,  SHI LEI ,  LEE CHIH-HUNG ,  MORTELL KATHLEEN H ,  SCHRIMPF MICHAEL R ,  LI TAO ,  SIPPY KEVIN B ,  GOPALAKRISHNAN MURALI ,  SCANIO MARC ,  DONNELLY-ROBERTS DIANA ,  HU MIN

IPC: C07D487/18 ,  A61K31/33 ,  A61P25/00

Abstract: La presente solicitud se refiere a derivados de indol e indolina de las fórmulas (I), (II), (III), (IV), (y), o (VI), en las cuales R1, R2, R3, R4, R5, U, V, W, X, Y, y Z son como se definen en la descripción. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, y a métodos para tratar condiciones patológicas utilizando dichos compuestos y composiciones, y a métodos para identificar dichos compuestos.

公开(公告)号：ZA201004689B

公开(公告)日：2011-03-30

申请号：ZA201004689

申请日：2010-07-02

Applicant: ABBOTT LAB

Inventor： HSIEH GIN C ,  ALTENBACH ROBERT J ,  WAKEFIELD BRIAN D ,  LIU HUAQING ,  GFESSER GREGORY A ,  BLACK LAWRENCE A ,  ZHAO CHEN ,  COWART MARLON D

公开(公告)号：MX2010006893A

公开(公告)日：2010-10-05

申请号：MX2010006893

申请日：2008-12-18

Applicant: ABBOTT LAB

Inventor： ALTENBACH ROBERT J ,  BLACK LAWRENCE A ,  COWART MARLON D ,  GFESSER GREGORY A ,  ZHAO CHEN ,  WAKEFIELD BRIAN D ,  LIU HUAQINQ ,  HSIEH GIN C

IPC: C07D413/04 ,  A61K31/423 ,  A61K31/428 ,  A61P3/10 ,  A61P25/00 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Se describen compuestos de la fórmula (I) que son útiles para tratar condiciones o trastornos evitados mediante o mejorados mediante ligandos del receptor histamina-3. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I), métodos para utilizar dichos compuestos y composiciones, y un procedimiento para preparar los compuestos.

公开(公告)号：UY32147A

公开(公告)日：2010-04-30

申请号：UY32147

申请日：2009-09-28

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  GFESSER GREGORY A ,  RAMIN FAGHIH ,  MORTELL KATHLEEN H ,  BUNNELLE WILLIAM H ,  LEE CHIN-HUNG ,  TAO LI ,  NERSESIAN DIANA L ,  MARC SCANIO ,  LEI SHI ,  MURALI GOPALAKRISHNAN ,  DONNELLY-ROBERTS DIANA ,  MIN HU

IPC: A61K31/4353 ,  A61K31/438 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  C07D471/04 ,  C07D471/06 ,  C07D487/04 ,  C07D487/06

Abstract: Derivados de indol y de indolita de fórmula (I), (II), (III), (IV), (V), o (VI) donde a R1, R2, R3, R4, R5, U, V, W, X, Y y Z son como los define la memoria descriptiva. Composiciones que comprenden estos compuestos, métodos para tratar condiciones de enfermedad mediante el uso de estos compuestos y de esta composiciones y métodos para identificar estos compuestos.

公开(公告)号：ZA200808757B

公开(公告)日：2010-03-31

申请号：ZA200808757

申请日：2008-10-14

Applicant: ABBOTT LAB

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  LYNCH CHRISTOPHER L ,  GOPALAKRISHNAN MURALI ,  GOPALAKRISHNAN SUJATHA ,  MALYSZ JOHN ,  GUBBINS EARL J ,  EL KOUHEN RACHID ,  LI JINHE

IPC: A61K20100101 ,  A61P20100101 ,  C07D20100101

Abstract: The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：CA2709676A1

公开(公告)日：2009-07-09

申请号：CA2709676

申请日：2008-12-19

Applicant: ABBOTT LAB

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  MORTELL KATHLEEN H ,  GOPALAKRISHNAN MURALI

IPC: C07D277/02 ,  A61P25/00 ,  C07D277/50

Abstract: The invention relates to novel thiazolylidine urea and amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

公开(公告)号：CA2566898A1

公开(公告)日：2005-12-01

申请号：CA2566898

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： NERSESIAN DIANA L ,  PU YU-MING ,  CURTIS MICHAEL P ,  BLACK LAWRENCE A ,  ALTENBACH ROBERT J ,  GFESSER GREGORY A ,  LUKIN KIRILL A ,  CHANG SOU-JEN ,  LIU HUAQING ,  KU YI-YIN ,  FAGHIH RAMIN ,  COWART MARLON D

IPC: C07D495/04 ,  A61K31/4709 ,  A61K31/4725 ,  C07D401/00 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/02 ,  C07D471/04 ,  C07D487/04 ,  C07D491/02 ,  C07D491/04 ,  C07D498/02 ,  C07D513/04

Abstract: Compounds of formula (I) wherein R 1 or R 2 is a tricyclic or bicyclic ring, each of which contains at least two hctcroatoms, and R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, X, X', Y, Y', Z, and Z' arc as defined hcrcin, arc useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：NZ586301A

公开(公告)日：2012-10-26

申请号：NZ58630108

申请日：2008-12-18

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  COWART MARLON D ,  GFESSER GREGORY A ,  WAKEFIELD BRIAN D ,  ALTENBACH ROBERT J ,  LIU HUAQING ,  ZHAO CHEN ,  HSIEH GIN C

IPC: C07D413/14 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61P3/10 ,  A61P25/00 ,  C07D277/82 ,  C07D417/14

Abstract: Disclosed are 2-(pyrrolidin-1-yl)benzo[d]thiazole derivatives as represented by the general formula (I), wherein Z is sulfur; n is an integer from 0 to 2; p is an integer from 0 to 1; and wherein the remaining substituents are as defined herein; and radiolabelled analogues thereof. Representative compounds include 6-(1-methyl-1H-pyrazol-4-yl)-2-(3-(piperidin-1-yl)azetidin-1-yl)benzo[d]thiazole, (R)-4-(2-(1,3'-bipyrrolidin-1'-yl)benzo[d]thiazol-6-yl)benzonitrile, (R)-6-(1-(11C)methyl-1H-pyrazol-4-yl)-2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazole, (R)-6-(1-methyl-1H-pyrazol-4-yl)-2-(3-(4-(18F)fluoro-piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazole, (R)-2-(2-(3-(4-(18F)fluoro-piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyridazin-3(2R)-one; (R)-3-(2-(3-(4-(18F)fluoro-piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)oxazolidin-2-one, (S)-3-hydroxy-1-(2-((R)-3-(4-(18F)fluoro-piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyrrolidin-2-one and (R)-N-(2-(18F)fluoroethyl)-2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazole-6-carboxamide. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above in combination with a pharmaceutically acceptable carrier for treating a condition or disorder modulated by the histamine-3 receptors selected from acute myocardial infarction, Alzheimer's disease, asthma, attention-deficit hyperactivity disorder, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, osteoarthritis pain, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and sleep disorders.